International Urology and Nephrology

, Volume 51, Issue 1, pp 27–32 | Cite as

The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study

  • Suleyman Sami CakirEmail author
  • Recep Burak Degirmentepe
  • Hasan Anil Atalay
  • Halil Lutfi Canat
  • Sait Ozbir
  • Mehmet Gokhan Culha
  • Emre Can Polat
  • Alper Otunctemur
Urology - Original Paper



The aim of the study was to determine the effect of anticholinergics used for overactive bladder treatment on the sexual function of women.


Between January 2016 and August 2018, over 18 years old, 216 sexual active women with OAB and 165 healthy women as control group were prospectively enrolled in the study. Five different anticholinergics were used for the treatment. Female Sexual Function Index (FSFI), eight-item overactive bladder awareness tool (OAB-V8), and Beck Depression Inventory form were completed before and after 3 months. Baseline and post-treatment scores were compared with a control group of age-matched healthy women.


Patients with OAB reported at baseline significantly worse sexual function in all FSFI domains compared to healthy control group (21.47 ± 3.22 vs. 26.79 ± 5.56, p < 0.01). Three months after treatment, over 85% of participants reported clinically relevant improvements in sexual function, with statistically significant changes in mean FSFI scores.


Treatment of OAB with anticholinergics can improve sexual function of sexual active women with OAB. Patients may be informed about this potential benefit of anticholinergic treatment, to improve their sexual function.


Anticholinergic Female sexual functions Overactive bladder 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN, International Urogynecological Association, International Continence Society (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 29(1):4–20. Google Scholar
  2. 2.
    Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P (2011) Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 108(7):1132–1138. CrossRefGoogle Scholar
  3. 3.
    Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I (2008) The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101(11):1388–1395. CrossRefGoogle Scholar
  4. 4.
    Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6):327–336. Google Scholar
  5. 5.
    Laumann EO, Paik A, Rosen RC (1999) Sexual dysfunction in the United States: prevalence and predictors. JAMA 281(6):537–544CrossRefGoogle Scholar
  6. 6.
    Read S, King M, Watson J (1997) Sexual dysfunction in primary medical care: prevalence, characteristics and detection by the general practitioner. J Public Health Med 19(4):387–391CrossRefGoogle Scholar
  7. 7.
    Kim YH, Seo JT, Yoon H (2005) The effect of overactive bladder syndrome on the sexual quality of life in Korean young and middle aged women. Int J Impot Res 17(2):158–163. CrossRefGoogle Scholar
  8. 8.
    Yip SK, Chan A, Pang S, Leung P, Tang C, Shek D, Chung T (2003) The impact of urodynamic stress incontinence and detrusor overactivity on marital relationship and sexual function. Am J Obstet Gynecol 188(5):1244–1248CrossRefGoogle Scholar
  9. 9.
    Patel AS, O’Leary ML, Stein RJ, Leng WW, Chancellor MB, Patel SG, Borello-France D (2006) The relationship between overactive bladder and sexual activity in women. Int Braz J Urol 32(1):77–87CrossRefGoogle Scholar
  10. 10.
    Coyne KS, Sexton CC, Thompson C, Kopp ZS, Milsom I, Kaplan SA (2011) The impact of OAB on sexual health in men and women: results from EpiLUTS. J Sex Med 8(6):1603–1615. CrossRefGoogle Scholar
  11. 11.
    Nambiar A, Lucas M (2014) Chapter 4: guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). Neurourol Urodyn 33(Suppl 3):S21–S25. CrossRefGoogle Scholar
  12. 12.
    Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological Association, Society of Urodynamics FPM (2015) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 193(5):1572–1580. CrossRefGoogle Scholar
  13. 13.
    Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54(3):543–562. CrossRefGoogle Scholar
  14. 14.
    Shen YC, Wang HJ, Chuang YC (2018) Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice. Int Urol Nephrol. Google Scholar
  15. 15.
    Zachariou A, Mamoulakis C, Filiponi M, Dimitriadis F, Giannakis J, Skouros S, Tsounapi P, Takenaka A, Sofikitis N (2018) The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study. BMC Urol 18(1):61CrossRefGoogle Scholar
  16. 16.
    Zachariou A, Filiponi M (2017) The effect of extended release tolterodine used for overactive bladder treatment on female sexual function. Int Braz J Urol 43(4):713–720. CrossRefGoogle Scholar
  17. 17.
    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A, Standardisation Sub-Committee of the International Continence S (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37–49CrossRefGoogle Scholar
  18. 18.
    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatr 4:561–571CrossRefGoogle Scholar
  19. 19.
    Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D’Agostino R Jr (2000) The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 26(2):191–208. CrossRefGoogle Scholar
  20. 20.
    Wiegel M, Meston C, Rosen R (2005) The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther 31(1):1–20. CrossRefGoogle Scholar
  21. 21.
    Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG (2005) Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 22(4):381–394CrossRefGoogle Scholar
  22. 22.
    Cohen BL, Barboglio P, Gousse A (2008) The impact of lower urinary tract symptoms and urinary incontinence on female sexual dysfunction using a validated instrument. J Sex Med 5(6):1418–1423. CrossRefGoogle Scholar
  23. 23.
    Hajebrahimi S, Azaripour A, Sadeghi-Bazargani H (2008) Tolterodine immediate release improves sexual function in women with overactive bladder. J Sex Med 5(12):2880–2885. CrossRefGoogle Scholar
  24. 24.
    Rogers R, Bachmann G, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T (2008) Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct 19(11):1551–1557. CrossRefGoogle Scholar
  25. 25.
    Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV (2006) The impact of the overactive bladder syndrome on sexual function: a preliminary report from the multicenter assessment of transdermal therapy in overactive bladder with oxybutynin trial. Am J Obstet Gynecol 195(6):1730–1735. CrossRefGoogle Scholar
  26. 26.
    Jha S (2016) Impact of treatment of overactive bladder with anticholinergics on sexual function. Arch Gynecol Obstet 293(2):403–406. CrossRefGoogle Scholar
  27. 27.
    Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. Google Scholar
  28. 28.
    Khullar V, Chapple C, Gabriel Z, Dooley JA (2006) The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 68(2 Suppl):38–48. CrossRefGoogle Scholar
  29. 29.
    Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ (2012) Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 1:CD005429. Google Scholar
  30. 30.
    Akino H, Namiki M, Suzuki K, Fuse H, Kitagawa Y, Miyazawa K, Fujiuchi Y, Yokoyama O (2014) Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study. Int J Urol 21(4):389–394CrossRefGoogle Scholar
  31. 31.
    van der Vaart CH, de Leeuw JR, Roovers JP, Heintz AP (2002) The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int 90(6):544–549CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Department of UrologyOkmeydani Training and Research HospitalIstanbulTurkey

Personalised recommendations